Interestingly, the combined application of GLP-1 and GIP resulted in a greater decrease in bone resorption than was seen with these hormones alone (Bergmann et al., 2019), suggesting that GLP-1/GIPR dual agonists, currently used as therapeutic agents for T2DM, may have significant antiresorptive effects (Frias et al., 2018). The gene discussed is GCG; the disease is type 2 diabetes mellitus.